Literature DB >> 8384074

Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer.

J L Nielsen1, J T Walsh, D R Degen, S M Drabek, J R McGill, D D von Hoff.   

Abstract

Amplification of cellular proto-oncogenes, important in tumor progression, has been correlated with a poor clinical outcome in a variety of human tumor types. Amplified genes are observed in two cytogenetically distinct entities, double minutes (DMs) and homogeneously staining regions (HSR). We examined 54 fresh lung tumor specimens obtained from patients with non-small cell lung cancer for cytogenetic evidence of gene amplification in the form of DMs. The majority of these patients had received no prior treatment. The cells were harvested within 24 hours after receiving the specimens, and the slides were stained with Giemsa to specifically look for DMs. We found DMs in 24 of 31 (77%) specimens that exhibited metaphase spreads. Similar incidences of DMs were found when histologic cell types, primary vs. non-primary tumors, and specimens from patients with prior treatment vs. no prior treatment were compared. Therefore, DMs occur frequently in non cultured lung tumor cells, providing evidence that gene amplification may be an important aspect of tumor behavior in patients with non-small cell lung carcinoma. Further investigation is warranted to identify the specific tumor-related genes located on these abnormal chromosomes. This also suggests that ongoing efforts to eliminate amplified drug-resistant genes or oncogenes contained on DMs in tumor cells may be relevant in patients with non-small cell lung cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8384074     DOI: 10.1016/0165-4608(93)90219-c

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity.

Authors:  Markus Rasmussen; Magnus Sundström; Hanna Göransson Kultima; Johan Botling; Patrick Micke; Helgi Birgisson; Bengt Glimelius; Anders Isaksson
Journal:  Genome Biol       Date:  2011-10-24       Impact factor: 13.583

2.  Extrachromosomal driver mutations in glioblastoma and low-grade glioma.

Authors:  Sergey Nikolaev; Federico Santoni; Marco Garieri; Periklis Makrythanasis; Emilie Falconnet; Michel Guipponi; Anne Vannier; Ivan Radovanovic; Frederique Bena; Françoise Forestier; Karl Schaller; Valerie Dutoit; Virginie Clement-Schatlo; Pierre-Yves Dietrich; Stylianos E Antonarakis
Journal:  Nat Commun       Date:  2014-12-04       Impact factor: 14.919

Review 3.  Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.

Authors:  Sweta Mishra; Johnathan R Whetstine
Journal:  Mol Cell Biol       Date:  2016-01-11       Impact factor: 4.272

Review 4.  Extrachromosomal Circular DNA: A New Target in Cancer.

Authors:  Pan Wu; Yuhang Liu; Ruijia Zhou; Lingyun Liu; Hongli Zeng; Fang Xiong; Shanshan Zhang; Zhaojian Gong; Wenling Zhang; Can Guo; Fuyan Wang; Ming Zhou; Xuyu Zu; Zhaoyang Zeng; Yong Li; Guiyuan Li; He Huang; Wei Xiong
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

5.  From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software.

Authors:  Michael Forster; Peter Forster; Abdou Elsharawy; Georg Hemmrich; Benjamin Kreck; Michael Wittig; Ingo Thomsen; Björn Stade; Matthias Barann; David Ellinghaus; Britt-Sabina Petersen; Sandra May; Espen Melum; Markus B Schilhabel; Andreas Keller; Stefan Schreiber; Philip Rosenstiel; Andre Franke
Journal:  Nucleic Acids Res       Date:  2012-09-10       Impact factor: 16.971

6.  Hprt mutants in a transplantable murine tumour arise more frequently in vivo than in vitro.

Authors:  D Wilkinson; J K Sandhu; J W Breneman; J D Tucker; H C Birnboim
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.